Clovis Oncology, Inc., along with its two affiliates filed first amended joint plan of liquidation with related disclosure statement in the US Bankruptcy Court on April 19, 2023. As per the plan filed, prepetition financing claims of $315.9 million shall recover 24.9% - 39.5%. Other priority claims are upto $0.05 million, other secured claims and Existing Securities Law Claims are for $0. Unsecured note claims of $447.90 million with expected recovery of 10.1% - 26.0% shall receive its pro rata share of the GUC CVRs.

U.S. general unsecured claim of $241.6 million – 304.9 million with expected recovery of 10.1% - 26.0% shall receive its pro rata share of the GUC CVRs. U.K. general unsecured claims of $191.5 million - $237.6 million and Ireland general unsecured claims of $191.3 million - $237.3 million shall not receive or retain any distribution under the plan on account of such claim. Intercompany claims are of $19.1 million and intercompany interests are of $3000.

There is no change in treatment of any other claim class or source of funding. Debtor, along with its two affiliates filed a modified first amended joint plan of liquidation with related disclosure statement in the US Bankruptcy Court on April 20, 2023. As per the plan filed, there is no change in treatment of any claim class or source of funding.

Debtor along with its two affiliates filed a solicitation version of modified first amended joint plan of liquidation with related disclosure statement in the US Bankruptcy Court on April 21, 2023. As per the plan filed, there is no change in treatment of any claim class or source of funding.